9.5 References
Bailey, C., Skouteris, H., Morris, H., O’Donnell, R., Hill, B., & Ademi, Z. (2021). Economic evaluation methods used in home-visiting interventions: a systematic search and review. Health & Social Care in the Community, 29(6), 1650–1667. https://doi.org/10.1111/hsc.13349
Berlin, N. L., Yost, M. L., Cheng, B., Henderson, J., Kerr, E., Nathan, H., & Dossett, L. A. (2021). Patterns and determinants of low-value preoperative testing in Michigan. JAMA Internal Medicine, 181(8), 1115–1118.
Bonner, S. (2022). Social cost benefit analysis and economic evaluation. University of Queensland Library. https://books.google.com.au/books?id=qjlYzwEACAAJ
Cliff, B. Q., Avancena, A. L., Hirth, R. A., & Lee, S. Y. D. (2021). The impact of Choosing Wisely interventions on low‐value medical services: a systematic review. The Milbank Quarterly, 99(4), 1024–1058.
Ferrando, A., Ivaldi, C., Buttiglieri, A., Pagano, E., Bonetto, C., Arione, R., … & Ciccone, G. (2005). Guidelines for preoperative assessment: impact on clinical practice and costs. International Journal for Quality in Health Care, 17(4), 323–329.
Flamm, M., Fritsch, G., Seer, J., Panisch, S., & Sönnichsen, A. C. (2011). Non-adherence to guidelines for preoperative testing in a secondary care hospital in Austria: the economic impact of unnecessary and double testing. European Journal of Anaesthesiology, 28(12), 867–873.
Grimshaw, J. M., Patey, A. M., Kirkham, K. R., Hall, A., Dowling, S. K., Rodondi, N., … & Bhatia, R. S. (2020). De-implementing wisely: developing the evidence base to reduce low-value care. BMJ Quality & Safety, 29(5), 409–417.
Heijnsdijk, E. A., Gulati, R., Tsodikov, A., Lange, J. M., Mariotto, A. B., Vickers, A. J., … & Etzioni, R. (2020). Lifetime benefits and harms of prostate-specific antigen–based risk-stratified screening for prostate cancer. Journal of the National Cancer Institute, 112(10), 1013–1020.
Hutubessy, R., Chisholm, D., Edejer, T. T.-T., & Who, C. (2003). Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Effectiveness and Resource Allocation, 1(1), 8. https://doi.org/10.1186/1478-7547-1-8
Hyatt, A., Chung, H., Aston, R., Gough, K., & Krishnasamy, M. (2022). Social return on investment economic evaluation of supportive care for lung cancer patients in acute care settings in Australia. BMC Health Services Research, 22(1), 1399. https://doi.org/10.1186/s12913-022-08800-x
Goodrich, K., Kaambwa, B., & Al-Janabi, H. (2012). The inclusion of informal care in applied economic evaluation: a review. Value in Health, 15(6), 975–981.
James, R., Salton, R. I., Byrnes, J. M., & Scuffham, P. A. (2017). Cost-utility analysis for bariatric surgery compared with usual care for the treatment of obesity in Australia. Surgery for Obesity and Related Diseases, 13(12), 2012–2020. https://doi.org/10.1016/j.soard.2016.12.016
Kuklinski, M. R., Briney, J. S., Hawkins, J. D. et al. (2012). Cost-benefit analysis of communities that care outcomes at eighth grade. Prevention Science, 13, 150–161. https://doi.org/10.1007/s11121-011-0259-9
Mariño, R. J., Fajardo, J., Calache, H., & Morgan, M. (2014). Cost-minimization analysis of a tailored oral health intervention designed for immigrant older adults. Geriatrics & Gerontology International, 14(2), 336–340. https://doi.org/10.1111/ggi.12103
Paschen, U., Sturtz, S., Fleer, D., Lampert, U., Skoetz, N., & Dahm, P. (2022). Assessment of prostate‐specific antigen screening: an evidence‐based report by the German Institute for Quality and Efficiency in Health Care. BJU International, 129(3), 280–289.
Robinson, R. (1993). Cost-utility analysis. British Medical Journal, 307(6908), 859–862. https://doi.org/10.1136/bmj.307.6908.859
Špacírová, Z., Epstein, D., García-Mochón, L., Rovira, J., Olry de Labry Lima, A., & Espín, J. (2020). A general framework for classifying costing methods for economic evaluation of health care. European Journal of Health Economics, 21(4), 529–542.
Scott, D. N., Palmer, M. A., Tidhar, M. T., Stoove, P. M., Sacks-Davis, D. R., Doyle, A. P. J. S., Pedrana, D. A., Thompson, P. A. J., Wilson, P. D. P., & Hellard, P. M. (2022). Assessment of the cost-effectiveness of Australia’s risk-sharing agreement for direct-acting antiviral treatments for hepatitis C: a modelling study. Lancet Regional Health – Western Pacific, 18, 100316. https://doi.org/10.1016/j.lanwpc.2021.100316
Sharma, D., Aggarwal, A. K., Downey, L. E., & Prinja, S. (2021). National healthcare economic evaluation guidelines: a cross-country comparison. PharmacoEconomics – Open, 5, 349–364.
The SROI Network. (2012). A guide to social return on investment. https://socialvalueuk.org/resource/a-guide-to-social-returnon-investment-2012/
Turner, H. C., Archer, R. A., Downey, L. E., Isaranuwatchai, W., Chalkidou, K., Jit, M., & Teerawattananon, Y. (2021). An introduction to the main types of economic evaluations used for informing priority setting and resource allocation in healthcare: key features, uses, and limitations. Frontiers in Public Health, 9, 722927.
Yang, Y., Abel, L., Buchanan, J., Fanshawe, T., & Shinkins, B. (2019). Use of decision modelling in economic evaluations of diagnostic tests: an appraisal and review of health technology assessments in the UK. PharmacoEconomics – Open, 3(3), 281–291.
